RNAing toward a new therapy for hemophilia

Bhavya S. Doshi,Robert F. Sidonio

DOI: https://doi.org/10.1182/blood.2024024295

IF: 20.3

2024-05-31

Blood

Abstract:In this issue of Blood , Kenet et al 1 report phase 3 trial results demonstrating safety and efficacy of once monthly fitusiran vs factor or bypassing agent (BPA) prophylaxis in patients with hemophilia without and with inhibitors, respectively.

hematology

What problem does this paper attempt to address?

Efficacy and Safety of Fitusiran Prophylaxis, an siRNA Therapeutic, in a Multicenter Phase 3 Study (ATLAS-INH) in People with Hemophilia A or B, with Inhibitors (PwHI)

Guy Young,Alok Srivastava,Kaan Kavakli,Cecil Ross,Jameela Sathar,Huyen Tran,Runhui Wu,Jing Sun,Stacey Poloskey,Zhiying Qui,Salim Kichou,Shauna R. Andersson,Baisong Mei,Savita Rangarajan

DOI: https://doi.org/10.1182/blood-2021-150273

IF: 20.3

2021-11-05

Blood

Abstract:Abstract Introduction Hemophilia A and B are rare bleeding disorders characterized by ineffective clot formation due to impaired thrombin generation as a result of deficiency of FVIII or FIX, respectively. Fitusiran is a subcutaneously (SC) administered investigational siRNA therapeutic targeting antithrombin to restore thrombin generation and rebalance hemostasis in people with hemophilia A or B, with or without inhibitors. Here, we present the safety and efficacy of fitusiran prophylaxis for PwHI in a phase 3 study (ATLAS-INH; NCT03417102). Methods The ATLAS-INH study is a randomized, open-label Phase 3 study designed to evaluate the efficacy and safety of fitusiran in PwHI. Eligible males ≥12 years receiving on-demand treatment with bypassing agents (BPA) were randomized in a 2:1 ratio to receive once monthly 80 mg SC fitusiran prophylaxis or continue with on-demand BPA. The primary endpoint is annualized bleeding rate (ABR) in PwHI on fitusiran prophylaxis compared to those on BPA on-demand in the efficacy period. The secondary endpoints include spontaneous ABR, joint ABR, and quality of life (QoL) measured by Haem-A-QoL. Results 57 subjects were randomized into the study. Mean (range) age of the study participants at screening was 28.4 (13-63) yrs. Statistical significance was achieved for primary and all secondary endpoints with significant reduction in ABRs of treated bleeds: all, spontaneous and joint bleeds for fitusiran vs on-demand BPA arm (Table 1). A total of 25 patients in fitusiran arm (65.8%) had zero treated bleeding events. Efficacy of fitusiran prophylaxis treatment was seen in both hemophilia A and hemophilia B patients with inhibitors. Statistical significance was also achieved for improvement in physical health domain score, with a difference (95% CI) of -28.72 (-39.07 to -18.37, p-value <0.0001) as well as overall HRQoL and between fitusiran and on-demand BPA arms. Overall, 38 patients (92.7%) in the fitusiran arm and 11 patients (57.9%) in the on-demand BPA arm experienced at least 1 treatment emergent adverse event (TEAE). A total of 13 treatment emergent serious adverse events (TESAEs) were reported in 7 patients (17.1%) in the fitusiran arm and 8 TESAEs were reported in 5 patients (26.3%) in the on-demand BPA arm. All TESAEs were reported in 1 patient each; in the fitusiran prophylaxis arm these included events of device related infection, hematuria, spinal vascular disorder, subclavian vein thrombosis, thrombosis, acute cholecystitis, chronic cholecystitis and asymptomatic COVID-19. One patient (2.4%) in the fitusiran arm experienced TEAEs that resulted in study drug discontinuation (spinal vascular disorder and thrombosis). There were no fatal TEAEs reported. Conclusions This Phase 3 study demonstrated the efficacy of the 80 mg monthly subcutaneous prophylaxis dose of fitusiran in people with hemophilia A or B with inhibitors. Specifically, fitusiran significantly reduced bleeding with a median ABR of zero and significant proportion of people with zero bleeds, resulting in a meaningful improvement in health-related quality of life. Reported TESAEs were generally consistent with what is anticipated in an adult and adolescent population with severe hemophilia A or B with inhibitors, or with the previously identified risks of fitusiran. A revised fitusiran dosing regimen with reduced dose and dose frequency is currently being evaluated in ongoing clinical studies. Figure 1 Figure 1. Disclosures Young: Genentech/Roche, Grifols, and Takeda: Research Funding; Apcintex, BioMarin, Genentech/Roche, Grifols, Novo Nordisk, Pfizer, Rani, Sanofi Genzyme, Spark, Takeda, and UniQure: Consultancy. Kavakli: Roche: Consultancy, Other: Clinical Trial Support; Novo Nordisk A/S: Consultancy, Other: Clinical Trial Support; Takeda: Consultancy, Other: Clinical Trial Support. Poloskey: Sanofi: Current Employment, Current equity holder in publicly-traded company. Qui: Sanofi: Current Employment, Current equity holder in publicly-traded company. Kichou: Sanofi: Current Employment, Current equity holder in publicly-traded company. Andersson: Sanofi: Current Employment, Current equity holder in publicly-traded company; WEST advisory committee member: Membership on an entity's Board of Directors or advisory committees. Mei: Sanofi: Current Employment, Current equity holder in publicly-traded company. Rangarajan: Sanofi: Other: Advisory Board; Pfizer: Other: Advisory Board; Reliance Life Sciences: Consultancy; Takeda: Other: Advisory Board, Conference Support, Speakers Bureau.

hematology
Fitusiran prophylaxis in people with hemophilia A or B who switched from prior BPA/CFC prophylaxis (ATLAS-PPX)

Gili Kenet,Beatrice Nolan,Osman Bülent Zülfikar,Bulent Antmen,Peter Kampmann,Tadashi Matsushita,Chur Woo You,Kateryna Vilchevska,Catherine N Bagot,Azizan Sharif,Flora Peyvandi,Guy Young,Claude G Negrier,Jiarui Chi,Barbara Kittner,Christian Sussebach,Fadi Shammas,Baisong Mei,Shauna Rita Andersson,Kaan Kavakli,Claude G. Negrier

DOI: https://doi.org/10.1182/blood.2023021864

IF: 20.3

2024-03-08

Blood

Abstract:Fitusiran prophylaxis provided consistent protection against bleeding vs prior BPA/CFC prophylaxis in PwHA/B, with or without inhibitors. Fitusiran was well tolerated, and reported adverse events were consistent with previously identified risks of fitusiran. Fitusiran, a subcutaneous (SC) investigational siRNA therapeutic, targets antithrombin to rebalance hemostasis in people with hemophilia A or B (PwHA/B), irrespective of inhibitor status. This Phase 3, open-label study (NCT03549871) evaluated the efficacy and safety of fitusiran prophylaxis in males aged ≥ 12 years with hemophilia A or B, with or without inhibitors, who received prior bypassing agent (BPA)/clotting factor concentrate (CFC) prophylaxis. Participants continued their prior BPA/CFC prophylaxis for 6 months before switching to once-monthly 80 mg fitusiran prophylaxis for 7 months (onset and efficacy periods). Primary endpoint was annualized bleeding rate (ABR) in the BPA/CFC prophylaxis and fitusiran efficacy period. Secondary endpoints included spontaneous ABR (AsBR) and joint ABR (AjBR). Safety and tolerability were assessed. Of 80 enrolled participants, 65 (inhibitor/non-inhibitor, n = 19/46) were eligible for ABR analyses. Observed median (IQR) ABRs were 6.5 (2.2, 19.6)/4.4 (2.2, 8.7) with BPA/CFC prophylaxis versus 0.0 (0.0, 0.0)/0.0 (0.0, 2.7) in the corresponding fitusiran efficacy period. Estimated mean ABRs were substantially reduced with fitusiran by 79.7% (P = 0.0021) and 46.4% (P = 0.0598) versus BPA/CFC prophylaxis, respectively. Forty-one participants (63.1%) experienced zero treated bleeds with fitusiran versus 11 (16.9%) with BPAs/CFCs. Median AsBR and AjBR were both 2.2 with BPA/CFC prophylaxis and 0.0 in the fitusiran efficacy period. Two participants (3.0%) experienced suspected or confirmed thromboembolic events with fitusiran. Once-monthly fitusiran prophylaxis significantly reduced bleeding events versus BPA/CFC prophylaxis in PwHA/B, with or without inhibitors and reported adverse events were generally consistent with previously identified risks of fitusiran.

hematology
An RNAi therapeutic targeting antithrombin to rebalance the coagulation system and promote hemostasis in hemophilia

Alfica Sehgal,Scott Barros,Lacramioara Ivanciu,Brian Cooley,June Qin,Tim Racie,Julia Hettinger,Mary Carioto,Yongfeng Jiang,Josh Brodsky,Harsha Prabhala,Xuemei Zhang,Husain Attarwala,Renta Hutabarat,Don Foster,Stuart Milstein,Klaus Charisse,Satya Kuchimanchi,Martin A Maier,Lubo Nechev,Pachamuthu Kandasamy,Alexander V Kel'in,Jayaprakash K Nair,Kallanthottathil G Rajeev,Muthiah Manoharan,Rachel Meyers,Benny Sorensen,Amy R Simon,Yesim Dargaud,Claude Negrier,Rodney M Camire,Akin Akinc

DOI: https://doi.org/10.1038/nm.3847

IF: 82.9

2015-04-13

Nature Medicine

Abstract:An siRNA targeting antithrombin promotes hemostasis in mouse and nonhuman primate models of hemophilia and could represent a new therapeutic option for this disease.

biochemistry & molecular biology,cell biology,medicine, research & experimental
Inhibition of Factor XI using a GalNAc-siRNA RBD5049: a novel antithrombotic drug with high potency and long duration

L. Gan,C. Li,Y. Sun,J. Wikstrom,Z. Guo,H. Yu,C. Tong,H. Zhang,Z. Liang,S. Gao

DOI: https://doi.org/10.1093/eurheartj/ehad655.2843

IF: 39.3

2023-01-01

European Heart Journal

Abstract:Abstract Introduction Bleeding risk remains a major concern of the existing anticoagulants. Inhibition Factor XI (FXI) using small molecule inhibitors, antibodies or antisense oligonucleotides (ASOs) to inactive intrinsic pathway of coagulation have been developed as a safer treatment option over the last decade. siRNA is a nucleic acid drug with class advantages of high selectivity, long duration and benign safety profiles. The current abstract summarizes key preclinical efficacy and safety data supporting the first-in-human study. Purpose To evaluate efficacy and safety, of a GalNAc-siRNA molecule RBD4059, for development of a novel antithrombotic treatment. Methods In vitro potency of several siRNAs were assessed and screened in HepG2 cells. Upon selection of the lead candidate, the siRNA was conjugated with a GalNAc molecule, using RIBO-GalSTAR liver targeting system. In vivo efficacy of RBD4059 was tested in C57BL/6J mice and cynomolgus non-human primates (NHPs). The antithrombotic effect of RBD4059 was determined in arterial and venous thrombosis models induced by FeCl3. Enoxaparin sodium (Lovenox) with clinical equivalent dose (4 mg/kg) was used as a control. Single- and repeated- dose GLP toxicology studies were performed in both CD-1 mice and NHPs. Results IC50 values of RBD4059 was 0.56 nM HepG2 cells. Dose-dependent and long-lasting effects of RBD4059 on the inhibition of plasma FXI activity (FXIa) were observed in mice and in NHPs. RBD4059 at a single dose of 9 mg/kg achieved a maximum of 89% plasma FXIa reduction and 1.38-fold APTT prolongation in mice, and the inhibitory effects could be maintained until Day 64. RBD4059 at 3 mg/kg or 9 mg/kg significantly prevented flow reduction due to FeCl3-induced thrombosis in both arterial and venous thrombosis models, and efficacy was superior than enoxaparin. In NHPs, the inhibitory effects of FXIa were maintained until Day 71 with the maximum effect of 77% FXIa reduction and 1.34-fold APTT prolongation. GLP toxicology studies showed good safety profile without any signs of increased bleeding despite supra-physiological doses and the NOAEL was considered 600 mg/kg in mice and 400 mg/kg in NHPs. Conclusions RBD4059 has demonstrated high potency/efficacy and long duration regarding FXI inhibition and with large safety margin. As the first siRNA based molecule targeting FXI, RBD4059 has now entered Phase 1 trial in human healthy volunteers.Figure 1
Non-factor Therapies for Hemophilia: Achievements and Perspectives

Victor Jiménez-Yuste

DOI: https://doi.org/10.1055/s-0044-1796651

2024-12-01

Seminars in Thrombosis and Hemostasis

Abstract:Non-factor replacement therapies (NFTs) have been developed to address the limitations of conventional replacement therapies, aiming to improve hemostasis and provide enhanced protection against bleeding episodes and long-term joint damage for patients both with and without inhibitors. Factor VIII (FVIII)-mimetic agents, such as emicizumab, have transformed the management of hemophilia A with inhibitors, offering a lower treatment burden and an effective alternative for those without inhibitors as well. Rebalancing agents, including anti-tissular factor pathway inhibitor agents (concizumab and marstacimab) and serpin inhibitors like fitusiran, have shown promising efficacy for patients with hemophilia B with inhibitors and other hemophilia subtypes. Administered subcutaneously, NFTs generate stable thrombin levels and feature a long half-life, which can shift severe hemophilia toward a milder phenotype. These therapies are effective regardless of inhibitor status and hold potential for application in other bleeding disorders. Evaluating the potential thrombotic risk after implementing mitigation measures, along with the development of anti-drug antibodies (ADAs), remain critical areas for further analysis. NFTs pose additional challenges due to their complex mechanism of action and the absence of a standardized laboratory assessment method. Unresolved issues include optimal management strategies for major surgeries and tailored approaches for safe use in older populations. This review highlights the progress and future potential of NFTs in treating persons with hemophilia. Article published online: 29 November 2024 © 2024. Thieme. All rights reserved. Thieme Medical Publishers, Inc. 333 Seventh Avenue, 18th Floor, New York, NY 10001, USA

peripheral vascular disease,hematology
Fitusiran, an Investigational siRNA Therapeutic Targeting Antithrombin for the Treatment of Hemophilia: First Results from a Phase 3 Study to Evaluate Efficacy and Safety in People with Hemophilia a or B without Inhibitors (ATLAS-A/B)

Alok Srivastava,Savita Rangarajan,Kaan Kavakli,Robert Klamroth,Gili Kenet,Liane Khoo,Chur-Woo You,Weiqun Xu,Niel Malan,Laurent Frenzel,Catherine N. Bagot,Oleksandra Stasyshyn,Chia-Yau Chang,Stacey Poloskey,Shauna Andersson,Zhiying Qiu,Baisong Mei,Steven W. Pipe

DOI: https://doi.org/10.1182/blood-2021-155018

IF: 20.3

2021-12-04

Blood

Abstract:Abstract Background Hemophilia is a rare bleeding disorder characterized by deficiency of FVIII or FIX resulting in ineffective clot formation due to impaired thrombin generation. Fitusiran is a subcutaneously (SC) administered investigational siRNA therapeutic agent which targets antithrombin to enhance thrombin generation potential and rebalance hemostasis in people with hemophilia (PwH), irrespective of inhibitor status. Here, we present results from a Phase 3 study of the efficacy and safety of fitusiran prophylaxis compared with on-demand (OD) treatment with factor concentrates in PwH A or B without inhibitors (ATLAS-A/B; NCT03417245). Methods This Phase 3, multicenter, multinational, randomized, open-label study evaluated the efficacy and safety of fitusiran in males aged ≥12 years with severe hemophilia A or B without inhibitors, previously treated OD. Eligible participants (pts) were randomized 2:1 to receive either once-monthly 80 mg SC fitusiran prophylaxis (fitusiran arm) or OD factor concentrates for treatment of bleeding episodes (OD arm) for a treatment period of 9 months. The primary endpoint was annualized bleeding rate (ABR) in the efficacy period (Day 29 post-first fitusiran dose up to Day 246). Secondary endpoints included annualized spontaneous bleeding rate (AsBR) and annualized joint bleeding rate (AJBR) in the efficacy period and health-related quality of life (HRQoL) in the treatment period, measured by Haem-A-QoL. Safety and tolerability were assessed throughout the study. Results Overall, 120 pts were randomized (fitusiran arm n=80; OD arm n=40); 79 pts (98.8%) in the fitusiran arm and 37 pts (92.5%) in the OD arm completed the study. A total of 93 pts had hemophilia A (fitusiran arm n=62, OD arm n=31) and 27 pts had hemophilia B (fitusiran arm n=18, OD arm n=9). Baseline demographics and characteristics were similar in both arms. Median observed ABR was 0.0 (IQR, 0.0 to 3.4) in the fitusiran arm and 21.8 (IQR, 8.4 to 41.0) in the OD arm; 40 pts (50.6%) in the fitusiran arm experienced no bleeds that required treatment with OD factor concentrates. A significant reduction in estimated ABR was achieved in the fitusiran arm vs the OD arm (89.9% reduction [95% CI, 84.1% to 93.6%], p<0.0001; Table). Median observed AsBR was 0.0 (IQR, 0.0 to 1.7) in the fitusiran arm and 16.1 (IQR, 3.4 to 27.6) in the OD arm. A significant reduction in estimated AsBR was achieved in the fitusiran arm vs the OD arm (91.7% reduction [95% CI, 85.9% to 95.1%], p<0.0001; Table). Median observed AJBR was 0.0 (IQR, 0.0 to 3.4) in the fitusiran arm and 15.9 (IQR, 4.2 to 33.5) in the OD arm. There was a significant reduction in estimated AJBR in the fitusiran arm vs the OD arm (90.3% reduction [95% CI, 83.9% to 94.1%], p<0.0001; Table). A significant improvement was also achieved in the transformed total and physical health score in the fitusiran arm vs the OD arm (LS mean difference -7.07 [95% CI, -11.23 to -2.90], p=0.0011; -19.75 [95% CI, -27.00 to -12.50], p<0.0001, respectively). Seventy-nine pts received at least 1 dose of fitusiran and 40 patients were randomized to the OD arm and included in the safety analysis. Overall, 62 pts (78.5%) in the fitusiran arm and 18 pts (45%) in the OD arm experienced ≥1 treatment emergent adverse event (TEAE). A total of 5 treatment emergent serious adverse events (TESAEs) were reported in 5 pts (6.3%) in the fitusiran arm and 9 TESAEs were reported in 5 pts (12.5%) in the OD arm. TESAEs in the fitusiran arm included cholelithiasis (2 pts, 2.5%), cholecystitis, lower respiratory tract infection, and asthma (1 pt each, 1.3%). In the fitusiran arm, 2 pts (2.5%) experienced TEAEs that resulted in fitusiran discontinuation (cholecystitis and increased alanine aminotransferase). No TEAEs of thrombosis and no fatal TEAEs were reported. Conclusions All key primary and secondary endpoints were met in this Phase 3 study. Specifically, once-monthly 80 mg SC fitusiran prophylaxis demonstrated a significant reduction in ABR, AsBR and AJBR (all ~90%) in people with severe hemophilia A or B without inhibitors compared with OD treatment. This reduction in bleeding was associated with a meaningful improvement in HRQoL. Reported TESAEs were generally consistent with previously identified risks of fitusiran. With the aim of further enhancing the benefit-risk profile of fitusiran, a revised regimen with reduced dose and frequency is currently being evaluated in ongoing clinical studies. Figure 1 Figure 1. Disclosures Srivastava: Roche: Other: Advisory Board, Research Funding; Novo Nordisk: Other: Advisory Board, Research Funding; Sanofi: Other: Advisory Board, Research Funding; Pfizer: Other: Advisory Board, Research Funding; Takeda: Other: Advisory Board, Research Funding; Bayer Healthcare: Other: Grant Review & Awards Committee. Rangarajan: Sanofi: Other: Advisory Board; Pfizer: Other: Advisory Board; Reliance Life Sciences: Consultancy; Takeda: Other: Advisory Board, Conference Support, Speakers Bureau. Kavakli: Pfizer, Bayer, Takeda, Roche, Novo Nordisk: Honoraria; Pfizer, Bayer, Roche, Novo Nordisk, Takeda: Speakers Bureau; Roche, Bayer, Pfizer, Novo Nordisk, Takeda: Membership on an entity's Board of Directors or advisory committees. Klamroth: Bayer, Leo: Research Funding; Bayer, Biotest, Biomarin, BMS, CSL Behring, Daiichi Sankyo, Leo, Novo Nordisk, Octapharma, Pfizer, Roche, Sanofi, SOBI, Takeda: Honoraria; Bayer, Biotest, Biomarin, BMS, CSL Behring, Daiichi Sankyo, Novo Nordisk, Octapharma, Pfizer, Roche, Sanofi, SOBI, Takeda: Speakers Bureau. Kenet: Alnylam: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; Bayer: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding, Speakers Bureau; Opko Biologics: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; Pfizer: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding, Speakers Bureau; Shire: Research Funding, Speakers Bureau; Novo Nordisk: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Roche: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding, Speakers Bureau; Takeda: Consultancy, Honoraria, Research Funding; Nat'l Hemophilia Ctr and Coagulation Unit and Amalia Biron Res Inst of Thromb & Hemost, Sheba Medical Ctr, Tel Hashomer, Israel: Current Employment; BioMarin Pharmaceutical: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; CSL: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Sanofi: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; Uniquore: Honoraria, Membership on an entity's Board of Directors or advisory committees; BPL: Research Funding. Khoo: NSW Health Pathology: Current Employment; Roche: Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding, Speakers Bureau; Novo Nordisk: Honoraria, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Sanofi: Honoraria, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Takeda: Speakers Bureau. You: Eulji University Hospital: Current Employment. Malan: PHOENIX Pharma (Pty) Ltd, Qgeberha, South Africa: Current Employment, Research Funding; St Francis Hospital, Qgeberha, South Africa: Membership on an entity's Board of Directors or advisory committees. Frenzel: Pfizer: Research Funding; Roche: Research Funding; SOBI: Research Funding; CSL Behring: Research Funding. Stasyshyn: CSL Behring: Consultancy, Honoraria, Research Funding, Speakers Bureau; Novo Nordisk: Consultancy, Research Funding, Speakers Bureau; Octapharma: Consultancy, Research Funding, Speakers Bureau; Pfizer: Consultancy, Research Funding, Speakers Bureau; Takeda: Consultancy, Research Funding, Speakers Bureau; Grifols: Consultancy, Speakers Bureau; Shire: Consultancy, Honoraria, Research Funding; Institute of Blood Pathology and Transfusion Medicine of National Academy of Medical Sciences of Ukraine: Current Employment; Sanofi: Honoraria, Research Funding; Roche: Speakers Bureau; LFB: Honoraria, Research Funding. Poloskey: Sanofi: Current Employment, Current equity holder in publicly-traded company. Andersson: Sanofi: Current Employment, Current equity holder in publicly-traded company; WEST advisory committee member: Membership on an entity's Board of Directors or advisory committees. Mei: Sanofi: Current Employment, Current equity holder in publicly-traded company, Divested equity in a private or publicly-traded company in the past 24 months, Patents & Royalties. Pipe: Sangamo Therapeutics: Consultancy, Membership on an entity's Board of Directors or advisory committees, Other: Scientific Advisory Board; ASC Therapeutics: Consultancy, Other: Scientific Advisory Board; Apcintex: Consultancy; Bayer: Consultancy; Biomarin: Consultancy; Catalyst Biosciences: Consultancy; CSL Behring: Consultancy; Freeline: Consultancy; Grifols: Consultancy; HEMA Biologics: Consultancy; Novo Nordisk: Consultancy; Octapharma: Consultancy; Pfizer: Consultancy; Roche/Genentech: Consultancy; Sanofi: Consultancy; Takeda: Consultancy; Spark Therapeutics: Consultancy; uniQure: Consultancy; GeneVentiv: Consultancy, Membership on an entity's Board of Directors or advisory committees; YewSavin: Research Funding; Siemens: Research Funding.

hematology
RNA-based Therapeutics: an Overview and Prospectus

Yiran Zhu,Liyuan Zhu,Xian Wang,Hongchuan Jin

DOI: https://doi.org/10.1038/s41419-022-05075-2

2022-01-01

Abstract:The growing understanding of RNA functions and their crucial roles in diseases promotes the application of various RNAs to selectively function on hitherto “undruggable” proteins, transcripts and genes, thus potentially broadening the therapeutic targets. Several RNA-based medications have been approved for clinical use, while others are still under investigation or preclinical trials. Various techniques have been explored to promote RNA intracellular trafficking and metabolic stability, despite significant challenges in developing RNA-based therapeutics. In this review, the mechanisms of action, challenges, solutions, and clinical application of RNA-based therapeutics have been comprehensively summarized.
Benefits and risks of non‐factor therapies: Redefining haemophilia treatment goals in the era of new technologies

Maria Elisa Mancuso,Stacy E. Croteau,Robert Klamroth

DOI: https://doi.org/10.1111/hae.14976

2024-03-15

Haemophilia

Abstract:Introduction Over the last decades progress in haemophilia treatment has been remarkable and prophylaxis with clotting factor concentrates in haemophilia A and B has been established as the standard of care in individuals with haemophilia and a severe bleeding phenotype. Besides clotting factor products with prolonged half‐life non‐factor therapies were developed which enable prophylaxis via subcutaneous administration. Factor VIIIa mimetics like emicizumab facilitate the coagulation pathway and are used in routine clinical practice for indivdiduals with haemophilia A. Rebalancing therapeutic agents like fitusiran, concizumab, marstacimab and serpin PC block the anticoagulant pathway and clinical trials using these products in individuals with haemophilia A and B are ongoing. Aim and Methods A narrative review to asess the benefits and risks of non‐factor therapies taking in to account re‐defined haemophilia treatment goals. Results Prophylaxis for prevention of bleeds using non‐factor products by subcutaneous administration is effective and results in reductions of bleeding episodes in individuals with haemophilia A or B with and without inhibitors. The treatment with emicizumab showed tolerable safety both in clinical trials and long‐term real‐world observations with few thrombotic events. In some clinical trials with rebalancing therapies (fitusiran and concizumab) thrombotic events occurred. Monitoring of the haemostatic function of novel therapies especially with concomitant haemostatic treatment is not yet established. Conclusion With the advent of novel therapeutic agents including factor concentrates with ultra‐long half‐life and improved FVIIIa mimetics aimed at raising the bar of protection into the non‐hemophilic range redefinition of haemophilia treatment goals is eagerly needed.

hematology
Hemophilia B and gene therapy: a new chapter with etranacogene dezaparvovec

Xavier M. Anguela,Katherine A. High

DOI: https://doi.org/10.1182/bloodadvances.2023010511

IF: 7.642

2024-04-11

Blood Advances

Abstract:Abstract The US Food and Drug Administration (FDA)’s authorization of etranacogene dezaparvovec (Hemgenix) is a significant milestone, constituting not only the first FDA approval of a gene therapy for hemophilia but also the first approval of a liver-targeted adeno-associated virus vector gene therapy. This review summarizes the nonclinical studies and clinical development that supported regulatory clearance. Similar to other gene therapies for single gene disorders, both the short-term safety and the phenotypic improvement were unequivocal, justifying the modest-sized safety and efficacy database, which included 57 participants across the phase 2b (3 participants) and phase 3 (54 participants) studies. The most common adverse reactions included liver enzyme elevation, headache, flu-like symptoms, infusion-related reactions, creatine kinase elevation, malaise, and fatigue; these were mostly transient. One participant had hepatocellular carcinoma on a study-mandated liver ultrasound conducted 1 year after vector infusion; molecular analysis of the resected tumor showed no evidence of vector-related insertional mutagenesis as the etiology. A remarkable 96% of participants in the phase 3 trial were able to stop factor IX (FIX) prophylaxis, with the study demonstrating noninferiority to FIX prophylaxis in terms of the primary end point, annualized bleeding rate. Key secondary end points such as the annualized infusion rate, which declined by 97%, and the plasma FIX activity level at 18 months after infusion, with least squares mean increase of 34.3 percentage points compared with baseline, were both clinically and statistically significant. The FDA’s landmark approval of Hemgenix as a pioneering treatment for hemophilia stands on the shoulders of >20 years of gene therapy clinical research and heralds a promising future for genomic medicines.

hematology
Gene therapy for hemophilia: looking beyond factor expression

Gabriela G Yamaguti-Hayakawa,Margareth C Ozelo

DOI: https://doi.org/10.1177/15353702221147565

2023-01-25

Experimental Biology and Medicine

Abstract:Experimental Biology and Medicine, Ahead of Print. Hemophilia A (factor VIII [FVIII] deficiency) and hemophilia B (factor IX [FIX] deficiency) are the X-linked recessive bleeding disorders that clinically manifest with recurrent bleeding, predominantly into muscles and joints. In its severe presentation, when factor activity is less than 1% of normal, hemophilia presents with spontaneous musculoskeletal bleeds and may progress to debilitating chronic arthropathy. Management of hemophilia has changed profoundly in the past decades. From on-demand to prophylactic factor concentrate replacement, the treatment goal shifted from controlling bleeds to preventing bleeds and improving quality of life. In this new scenario, gene therapy has arisen as a paradigm-changing therapeutic option, a one-time treatment with the potential to achieve sustained coagulation FVIII or FIX expression even within the normal range. This review discusses the critical impact of adeno-associated virus (AAV) gene transfer in hemophilia care, including the recent clinical outcomes, changes in disease perceptions, and its treatment burden. We also discuss the challenging scenario of the AAV-directed immune response in the clinical setting and potential strategies to improve the long-lasting efficacy of hemophilia gene therapy efficacy.

medicine, research & experimental
FIX It in One Go: Enhanced Factor IX Gene Therapy for Hemophilia B

David Lillicrap

DOI: https://doi.org/10.1016/j.cell.2017.11.049

IF: 64.5

2017-12-14

Cell

Abstract:A phase 1/2 clinical trial of AAV-mediated gene therapy in patients with hemophilia B using an enhanced specific activity factor IX (FIX) transgene reports sustained levels of FIX levels, leading to the near elimination of bleeding for more than a year and without serious adverse side effects. These results are the best outcome to date for hemophilia gene therapy.
Safety and activity of an engineered, liver-tropic adeno-associated virus vector expressing a hyperactive Padua factor IX administered with prophylactic glucocorticoids in patients with haemophilia B: a single-centre, single-arm, phase 1, pilot trial

Feng Xue,Huiyuan Li,Xia Wu,Wei Liu,Feixu Zhang,Dingyue Tang,Yunfei Chen,Wentian Wang,Ying Chi,Jing Zheng,Zengmin Du,Wei Jiang,Chen Zhong,Jun Wei,Ping Zhu,Rongfeng Fu,Xiaofan Liu,Lingling Chen,Xiaolei Pei,Junjiang Sun,Tao Cheng,Renchi Yang,Xiao Xiao,Lei Zhang

DOI: https://doi.org/10.1016/S2352-3026(22)00113-2

IF: 30.153

2022-01-01

The Lancet Haematology

Abstract:Background A novel, engineered, liver-tropic adeno-associated virus vector expressing a hyperactive Padua factor IX (FIX) protein (BBM-H901) has been developed and is promising for haemophilia B gene therapy. We aimed to explore its safety and activity in increasing FIX concentrations and reducing bleeding frequency. Methods We did a single-centre, single-arm, phase 1, pilot trial evaluating the safety and activity of a single intravenous infusion of BBM-H901 at the Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College (Tianjin, China). We enrolled adult patients with haemophilia B (aged >18 years) with baseline FIX coagulation activity (FIX:C) of less than 2 IU/dL, no FIX inhibitor, and low titre of neutralising antibodies (<= 1:4) against vector capsid. Eligible participants were intravenously infused with a single dose of 5 x10(12) vector genomes (vg)/kg of BBM-H901 after 1 week of prophylactic prednisone treatment (1 mg/kg per day). Primary endpoints were the incidence of treatment-related adverse events, change in alanine aminotransferase (ALT) and aspartate amino transferase (AST), and development of antibodies against vector capsid within 1 year of infusion. We report the results of the prespecified 1-year analysis following complete enrolment. The trial is registered with ClinicalTrials.gov , NCT04135300, and is complete. Findings Between Oct 16, 2019, and Jan 13, 2021, 12 male participants were assessed, and ten Chinese participants were enrolled and infused with BBM-H901. After a median follow-up of 58 weeks (IQR 51.5-99.5), mean FIX:C reached mean 36.9 IU/dL (SD 20.5). No serious adverse events, no grade 3-4 adverse events were observed. Grade 1-2 adverse events related to BBM-H901 include pyrexia (1 [10%]) and elevation of aminotransferase (1 [10%]). No FIX inhibitors were observed. All participants developed antibodies against vector capsid after infusion. Eight (80%) participants had All and AST concentrations below the upper limit of normal throughout the follow-up period. Two (20%) participants had elevation of ALT and AST accompanied with decrease of FIX:C, which remained at 7 IU/dL and 11.8 IU/dL, respectively. Interpretation This pilot study suggests that liver-tropic BBM-H901 is safe 1 year after infusion. Vector derived FIX:C concentration is sufficiently high to prevent bleeding events and minimise the need for replacement therapy in small populations with haemophilia B. These findings support further study. Copyright (C) 2022 Published by Elsevier Ltd. All rights reserved.
Prophylaxis with recombinant factor IX Fc fusion protein reduces the risk of bleeding and delays time to first spontaneous bleed event in previously untreated patients with haemophilia B: A post hoc analysis of the PUPs B‐LONG study

Beatrice Nolan,Michael Recht,Pablo Rendo,Aletta Falk,Meredith Foster,Sandra Casiano,Antoine Rauch,Amy Shapiro

DOI: https://doi.org/10.1111/ejh.14252

2024-06-26

European Journal Of Haematology

Abstract:Objectives Haemophilia B (HB), characterised by deficient factor IX (FIX), leads to spontaneous bleeds. Severe cases require prophylactic FIX replacement. This post hoc analysis assessed the first spontaneous bleeds among previously untreated patients (PUPs) with HB treated with recombinant FIX Fc fusion protein (rFIXFc) (NCT02234310) to identify factors influencing bleeds. Methods Subjects included paediatric PUPs with HB (≤2 IU/dL endogenous FIX). Analyses described treatment patterns (on demand [OD] vs. prophylaxis) and prophylaxis type (started on vs. switched to prophylaxis). Kaplan–Meier analyses assessed the time to first spontaneous bleed, including median time to event and fitting models with predictors for treatment regimen and/or baseline age. Results PUPs B‐LONG enrolled 33 subjects. Baseline age did not influence the time to first spontaneous bleed for any rFIXFc regimen. Those who started on prophylaxis with rFIXFc (n = 11), compared with those treated OD (n = 22), had an extended time to first spontaneous bleed. Starting prophylaxis afforded a 93% reduced risk of first spontaneous bleed versus starting OD (hazard ratio [95% confidence interval]: 0.071 [0.009–0.592]) (p = .015). Conclusion rFIXFc prophylaxis, particularly starting early, reduced the risk of bleeding and delayed time to first spontaneous bleed compared with rFIXFc OD. Hence, initial treatment regimens impact bleed patterns in paediatric PUPs.

hematology
RNA Therapeutics - Research and Clinical Advancements

Rundong Feng,Suryaji Patil,Xin Zhao,Zhiping Miao,Airong Qian

DOI: https://doi.org/10.3389/fmolb.2021.710738

IF: 6.113

2021-09-22

Frontiers in Molecular Biosciences

Abstract:RNA therapeutics involve the use of coding RNA such as mRNA as well as non-coding RNAs such as small interfering RNAs (siRNA), antisense oligonucleotides (ASO) to target mRNA, aptamers, ribozymes, and clustered regularly interspaced short palindromic repeats-CRISPR-associated (CRISPR/Cas) endonuclease to target proteins and DNA. Due to their diverse targeting ability and research in RNA modification and delivery systems, RNA-based formulations have emerged as suitable treatment options for many diseases. Therefore, in this article, we have summarized different RNA therapeutics, their targeting strategies, and clinical progress for various diseases as well as limitations; so that it might help researchers formulate new and advanced RNA therapeutics for various diseases. Additionally, U.S. Food and Drug Administration (USFDA)-approved RNA-based therapeutics have also been discussed.

biochemistry & molecular biology
A treatment bridge for infants with hemophilia

Thomas C. Abshire

DOI: https://doi.org/10.1182/blood.2023023576

IF: 20.3

2024-04-05

Blood

Abstract:In this issue of Blood , Pipe et al 1 report on the high safety and efficacy of emicizumab, a recombinant, humanized, bispecific monoclonal antibody, in children <1 year of age with severe hemophilia A (HA) (<1% factor VIII [FVIII]) and without FVIII antibodies (inhibitors). This novel, practice-changing, large-study finding, not reported previously in the infant age group, is described in this multicenter, phase 3b, open-label, single-arm study. Long-term data will be collected over the next 7 years.

hematology
AAV mediated genome engineering with a bypass coagulation factor alleviates the bleeding phenotype in a murine model of hemophilia B

Pratiksha Sarangi,Narendra Kumar,Ramkumar Sambasivan,Sivaprakash Ramalingam,Sonal Amit,Dinesh Chandra,Giridhara R Jayandharan

DOI: https://doi.org/10.1016/j.thromres.2024.04.031

Abstract:It is crucial to develop a long-term therapy that targets hemophilia A and B, including inhibitor-positive patients. We have developed an Adeno-associated virus (AAV) based strategy to integrate the bypass coagulation factor, activated FVII (murine, mFVIIa) gene into the Rosa26 locus using Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/Cas9 mediated gene-editing. AAV vectors designed for expression of guide RNA (AAV8-gRNA), Cas9 (AAV2 neddylation mutant-Cas9), and mFVIIa (AAV8-mFVIIa) flanked by homology arms of the target locus were validated in vitro. Hemophilia B mice were administered with AAV carrying gRNA, Cas9 (1 × 1011 vgs/mouse), and mFVIIa with homology arms (2 × 1011 vgs/mouse) with appropriate controls. Functional rescue was documented with suitable coagulation assays at various time points. The data from the T7 endonuclease assay revealed a cleavage efficiency of 20-42 %. Further, DNA sequencing confirmed the targeted integration of mFVIIa into the safe-harbor Rosa26 locus. The prothrombin time (PT) assay revealed a significant reduction in PT in mice that received the gene-editing vectors (22 %), and a 13 % decline in mice that received only the AAV-FVIIa when compared to mock treated mice, 8 weeks after vector administration. Furthermore, FVIIa activity in mice that received triple gene-editing vectors was higher (122.5mIU/mL vs 28.8mIU/mL) than the mock group up to 15 weeks post vector administration. A hemostatic challenge by tail clip assay revealed that hemophilia B mice injected with only FVIIa or the gene-editing vectors had significant reduction in blood loss. In conclusion, AAV based gene-editing facilitates sustained expression of coagulation FVIIa and phenotypic rescue in hemophilia B mice.
Non-clotting factor therapies for preventing bleeds in people with congenital hemophilia A or B

Omotola O Olasupo,Noella Noronha,Megan S Lowe,Derek Ansel,Mihir Bhatt,Davide Matino

DOI: https://doi.org/10.1002/14651858.cd014544.pub2

IF: 8.4

2024-02-28

Cochrane Database of Systematic Reviews

Abstract:Management of congenital hemophilia A and B is by prophylactic or on‐demand replacement therapy with clotting factor concentrates. The effects of newer non‐clotting factor therapies such as emicizumab, concizumab, marstacimab, and fitusiran compared with existing standards of care are yet to be systematically reviewed. To assess the effects (clinical, economic, patient‐reported, and adverse outcomes) of non‐clotting factor therapies for preventing bleeding and bleeding‐related complications in people with congenital hemophilia A or B compared with prophylaxis with clotting factor therapies, bypassing agents, placebo, or no prophylaxis. We searched the Cochrane Cystic Fibrosis and Genetic Disorders Group's Coagulopathies Trials Register, electronic databases, conference proceedings, and reference lists of relevant articles and reviews. The date of the last search was 16 August 2023. Randomized controlled trials (RCTs) evaluating people with congenital hemophilia A or B with and without inhibitors, who were treated with non‐clotting factor therapies to prevent bleeds. Two review authors independently reviewed studies for eligibility, assessed risk of bias, and extracted data for the primary outcomes (bleeding rates, health‐related quality of life (HRQoL), adverse events) and secondary outcomes (joint health, pain scores, and economic outcomes). We assessed the mean difference (MD), risk ratio (RR), 95% confidence interval (CI) of effect estimates, and evaluated the certainty of the evidence using GRADE. Six RCTs (including 397 males aged 12 to 75 years) were eligible for inclusion. Prophylaxis versus on‐demand therapy in people with inhibitors Four trials (189 participants) compared emicizumab, fitusiran, and concizumab with on‐demand therapy in people with inhibitors. Prophylaxis using emicizumab likely reduced annualized bleeding rates (ABR) for all bleeds (MD −22.80, 95% CI −37.39 to −8.21), treated bleeds (MD −20.40, 95% CI −35.19 to −5.61), and annualized spontaneous bleeds (MD −15.50, 95% CI −24.06 to −6.94), but did not significantly reduce annualized joint and target joint bleeding rates (AjBR and AtjBR) (1 trial; 53 participants; moderate‐certainty evidence). Fitusiran also likely reduced ABR for all bleeds (MD −28.80, 95% CI −40.07 to −17.53), treated bleeds (MD −16.80, 95% CI −25.80 to −7.80), joint bleeds (MD −12.50, 95% CI −19.91 to −5.09), and spontaneous bleeds (MD −14.80, 95% CI −24.90 to −4.71; 1 trial; 57 participants; moderate‐certainty evidence). No evidence was available on the effect of bleed prophylaxis using fitusiran versus on‐demand therapy on AtjBR. Concizumab may reduce ABR for all bleeds (MD −12.31, 95% CI −19.17 to −5.45), treated bleeds (MD −10.10, 95% CI −17.74 to −2.46), joint bleeds (MD −9.55, 95% CI −13.55 to −5.55), and spontaneous bleeds (MD −11.96, 95% CI −19.89 to −4.03; 2 trials; 78 participants; very low‐certainty evidence), but not target joint bleeds (MD −1.00, 95% CI −3.26 to 1.26). Emicizumab prophylaxis resulted in an 11.31‐fold increase, fitusiran in a 12.5‐fold increase, and concizumab in a 1.59‐fold increase in the proportion of participants with no bleeds. HRQoL measured using the Haemophilia Quality of Life Questionnaire for Adults (Haem‐A‐QoL) physical and total health scores was improved with emicizumab, fitusiran, and concizumab prophylaxis (low‐certainty evidence). Non‐serious adverse events were higher with non‐clotting factor therapies versus on‐demand therapy, with injection site reactions being the most frequently reported adverse events. Transient antidrug antibodies were reported for fitusiran and concizumab. Prophylaxis versus on‐demand therapy in people without inhibitors Two trials (208 participants) compared emicizumab and fitusiran with on‐demand therapy in people without inhibitors. One trial assessed two doses of emicizumab (1.5 mg/kg weekly and 3.0 mg/kg bi‐weekly). Fitusiran 80 mg monthly, emicizumab 1.5 mg/kg/week, and emicizumab 3.0 mg/kg bi‐weekly all likely resulted in a large reduction in ABR for all bleeds, all treated bleeds, and joint bleeds. AtjBR was not reduced with either of the emicizumab dosing regimens. The effect of fitusiran prophylaxis on target joint bleeds was not assessed. Spontaneous bleeds were likely reduced with fitusiran (MD −20.21, 95% CI –32.12 to −8.30) and emicizumab 3.0 mg/kg bi‐weekly (MD −15.30, 95% CI −30.46 to −0.14), but not with emicizumab 1.5 mg/kg/week (MD –14.60, 95% CI –29.78 to 0.58). The percentage of participants with zero bleeds was higher following emicizumab 1.5 mg/kg/week (50% versus 0%), emicizumab 3.0 mg/kg bi‐weekly (40% versus 0%), and fitusiran prophylaxis (40% versus 5%) compared with on‐demand therapy. Emicizumab 1.5 mg/kg/week did not improve Haem‐A‐QoL physical and total health scores, EQ‐5D‐5L VAS, or utility index scores (low‐certainty evidence) when compared with on‐demand therapy at 25 weeks. Emicizum -Abstract Truncated-

medicine, general & internal
Factor Replacement Treatment for Hemophilia A: Achievements and Perspectives

Maria Elisa Mancuso

DOI: https://doi.org/10.1055/s-0044-1791778

2024-10-16

Seminars in Thrombosis and Hemostasis

Abstract:The mainstay of treatment for persons with hemophilia A (PwHA) with severe bleeding phenotype is prophylaxis. The pharmacokinetic (PK) profile of native factor VIII (FVIII) imposes the need for rather frequent intravenous injections to ensure effective prophylaxis, but this represents a relevant treatment burden and is associated with suboptimal adherence to treatment. In this light, the advent of extended half-life (EHL) FVIII molecules has improved prophylaxis feasibility and outcomes by favoring treatment individualization and tailoring protection according to specific clinical and nonclinical needs. Different technologies have been used to enhance FVIII PK properties including Fc-fusion and conjugation with polyethylene glycol. Data from clinical development programs for such molecules, together with growing real-world experience, have shown numerous benefits related to the use of EHL FVIII in PwHA. Recently a new class of ultra-long-acting EHL FVIII has been developed to further improve protection against bleeding episodes and achieve the ambitious goal of providing PwHA with hemostatic protection in the nonhemophilia range over longer time periods, hence ensuring very low bleeding rates and improving joint health and quality of life. In this review, the achievements and perspectives of replacement therapies for PwHA are summarized and discussed. Article published online: 14 October 2024 © 2024. Thieme. All rights reserved. Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

peripheral vascular disease,hematology
Real‐world outcomes with recombinant factor IX Fc fusion protein (rFIXFc) prophylaxis: Longitudinal follow‐up in a national adult cohort

Mairead O'Donovan,Catherine Bergin,Eimear Quinn,Evelyn Singleton,Sheila Roche,Julie Benson,Rachel Bird,Mary Byrne,Cleona Duggan,Ruth Gilmore,Kevin Ryan,James S. O'Donnell,Niamh M. O’Connell

DOI: https://doi.org/10.1111/hae.14307

2021-05-03

Haemophilia

Abstract:<section class="article-section__content"><h3 class="article-section__sub-title section1"> Introduction</h3><p>In 2017, all people with severe haemophilia B (PWSHB) in Ireland switched from standard half‐life (SHL) recombinant FIX (rFIX) to rFIX Fc fusion protein (rFIXFc) prophylaxis.</p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Aims</h3><p>To evaluate prophylaxis regimens, bleeding rates and factor usage for two years of rFIXFc prophylaxis in a real‐world setting.</p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Methods</h3><p>Data collected retrospectively from electronic diaries and medical records of PWSHB for a two‐year period on rFIXFc prophylaxis were compared with paired baseline data on SHL rFIX treatment.</p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Results</h3><p>28 PWSHB (≥18 years) were enrolled, and at switchover 79% were receiving prophylaxis and 21% episodic treatment with SHL rFIX. At 24 months following switchover, all remained on rFIXFc prophylaxis with reduced infusion frequency; median dose per infusion once weekly (55 IU/kg, 20/28), every 10 days (63 IU/kg, 2/28) or every 14 days (98 IU/kg, 6/28). Median annualised bleed rate improved significantly on rFIXFc prophylaxis (2.0 versus 3.3 on SHL FIX) (<i>p </i>= 0.01). Median FIX trough level with once‐weekly infusions was 0.09 IU/ml (0.06–0.14 IU/ml). Management of bleeding episodes was similar with rFIXFc and SHL rFIX; one infusion was sufficient to treat 74% and 77% of bleeds, respectively, with similar total median treatment per bleeding episode. Factor consumption reduced by 28% with rFIXFc prophylaxis (57 IU/kg/week, range 40–86 IU/kg/week) compared with SHL rFIX (79 IU/kg/week, range 44–210 IU/kg/week) (<i>p </i>= 0.002). </p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Conclusion</h3><p>This study provides important insights into real‐world experience of switching to rFIXFc prophylaxis in an adult population, demonstrating high rates of prophylaxis, with reduced infusion frequency, bleeding and FIX consumption.</p></section>

hematology
RNA therapeutics for the treatment of blood disorders

Anh Dao Ngo,Hoang Lam Nguyen,Safak Caglayan,Dinh-Toi Chu

DOI: https://doi.org/10.1016/bs.pmbts.2023.11.005

2024-01-27

Progress in Molecular Biology and Translational Science

Abstract:Blood disorders are defined as diseases related to the structure, function, and formation of blood cells. These diseases lead to increased years of life loss, reduced quality of life, and increased financial burden for social security systems around the world. Common blood disorder treatments such as using chemical drugs, organ transplants, or stem cell therapy have not yet approached the best goals, and treatment costs are also very high. RNA with a research history dating back several decades has emerged as a potential method to treat hematological diseases. A number of clinical trials have been conducted to pave the way for the use of RNA molecules to cure blood disorders. This novel approach takes advantage of regulatory mechanisms and the versatility of RNA-based oligonucleotides to target genes and cellular pathways involved in the pathogenesis of specific diseases. Despite positive results, currently, there is no RNA drug to treat blood-related diseases approved or marketed. Before the clinical adoption of RNA-based therapies, challenges such as safe delivery of RNA molecules to the target site and off-target effects of injected RNA in the body need to be addressed. In brief, RNA-based therapies open novel avenues for the treatment of hematological diseases, and clinical trials for approval and practical use of RNA-targeted are crucial.

biochemistry & molecular biology

RNAing toward a new therapy for hemophilia

Efficacy and Safety of Fitusiran Prophylaxis, an siRNA Therapeutic, in a Multicenter Phase 3 Study (ATLAS-INH) in People with Hemophilia A or B, with Inhibitors (PwHI)

Fitusiran prophylaxis in people with hemophilia A or B who switched from prior BPA/CFC prophylaxis (ATLAS-PPX)

An RNAi therapeutic targeting antithrombin to rebalance the coagulation system and promote hemostasis in hemophilia

Inhibition of Factor XI using a GalNAc-siRNA RBD5049: a novel antithrombotic drug with high potency and long duration

Non-factor Therapies for Hemophilia: Achievements and Perspectives

Fitusiran, an Investigational siRNA Therapeutic Targeting Antithrombin for the Treatment of Hemophilia: First Results from a Phase 3 Study to Evaluate Efficacy and Safety in People with Hemophilia a or B without Inhibitors (ATLAS-A/B)

RNA-based Therapeutics: an Overview and Prospectus

Benefits and risks of non‐factor therapies: Redefining haemophilia treatment goals in the era of new technologies

Hemophilia B and gene therapy: a new chapter with etranacogene dezaparvovec

Gene therapy for hemophilia: looking beyond factor expression

FIX It in One Go: Enhanced Factor IX Gene Therapy for Hemophilia B

Safety and activity of an engineered, liver-tropic adeno-associated virus vector expressing a hyperactive Padua factor IX administered with prophylactic glucocorticoids in patients with haemophilia B: a single-centre, single-arm, phase 1, pilot trial

Prophylaxis with recombinant factor IX Fc fusion protein reduces the risk of bleeding and delays time to first spontaneous bleed event in previously untreated patients with haemophilia B: A post hoc analysis of the PUPs B‐LONG study

RNA Therapeutics - Research and Clinical Advancements

A treatment bridge for infants with hemophilia

AAV mediated genome engineering with a bypass coagulation factor alleviates the bleeding phenotype in a murine model of hemophilia B

Non-clotting factor therapies for preventing bleeds in people with congenital hemophilia A or B

Factor Replacement Treatment for Hemophilia A: Achievements and Perspectives

Real‐world outcomes with recombinant factor IX Fc fusion protein (rFIXFc) prophylaxis: Longitudinal follow‐up in a national adult cohort

RNA therapeutics for the treatment of blood disorders